SiteOne Therapeutics is a clinical-stage biopharmaceutical company developing therapeutics for the treatment of hypersensitivity disorders such as chronic cough, itch and pain. Our drug candidates are exquisitely selective inhibitors of voltage-gated sodium ion channels that are under investigation for the treatment of multiple neurogenic diseases by systemic and local routes of administration.

Chronic Cough and Chronic Pain

Learn how SiteOne is developing a completely new class of non-opioid treatments which selectively interrupt electrical signals from hyperexcitable, peripheral sensory nerves before they engage the central nervous system.

Voltage-Gated Sodium Channels

SiteOne's unique approach has enabled the discovery of exquisitely-selective small molecule inhibitors of Nav1.7 and Nav1.8, the primary voltage-gated sodium channel isoforms involved in peripheral hypersensitivity disorders.

News & Updates

Read more about the progress of SiteOne’s research and development programs